5900-13-0

Basic information

• Product Name: 5-BROMO-3-METHOXYPYRAZIN-2-YLAMINE
• Synonyms: 2-AMINO-5-BROMO-3-METHOXYPYRAZINE;5-BROMO-3-METHOXYPYRAZIN-2-YLAMINE;5-BROMO-3-METHOXYPYRAZIN-2-YLAMINE, 95+%;3-Methoxy-5-bromopyrazin-2-amine;5-Bromo-3-methoxy-2-pyrazinamine;2-Amino-5-Bromo-3-methoxypyrazin;5-BROMO-3-METHOXYPYR;5-bromo-3-methoxypyrazin-2-amine
• CAS NO: 5900-13-0
• Molecular Formula: C₅H₆BrN₃O
• Molecular Weight: 204.02
• Product Categories: amine|alkyl bromide
• Mol File: 5900-13-0.mol
• Article Data: 12

Chemical Properties

• Melting Point: 138 ºC
• Boiling Point: 262 ºC
• Flash Point: 112 ºC
• Appearance: /
• Density: 1.723
• Vapor Pressure: 0.0113mmHg at 25°C
• Refractive Index: 1.
• Storage Temp.: 2-8°C
• Solubility: DMSO, Methanol
• PKA: 1.93±0.10(Predicted)
• CAS DataBase Reference: 5-BROMO-3-METHOXYPYRAZIN-2-YLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-3-METHOXYPYRAZIN-2-YLAMINE(5900-13-0)
• EPA Substance Registry System: 5-BROMO-3-METHOXYPYRAZIN-2-YLAMINE(5900-13-0)

Safety Data

• Hazard Codes: Xn
• Statements: 22-37/38-41
• Safety Statements: 26-39
• WGK Germany: 3
• Hazardous Substances Data: 5900-13-0(Hazardous Substances Data)

Usage

Description

5-BROMO-3-METHOXYPYRAZIN-2-YLAMINE is an off-white solid that serves as an intermediate in the synthesis of N-pyrazinylbenzenesulfonamides, which are utilized in the treatment of chemokine mediated diseases.

Uses

Used in Pharmaceutical Industry:
5-BROMO-3-METHOXYPYRAZIN-2-YLAMINE is used as a chemical intermediate for the development of N-pyrazinylbenzenesulfonamides, which are crucial in the treatment of chemokine mediated diseases such as asthma. Its role in the synthesis process is vital for creating effective medications that can help manage and alleviate the symptoms of these conditions.

InChI:InChI=1/C5H6BrN3O/c1-10-5-4(7)8-2-3(6)9-5/h2H,1H3,(H2,7,8)

Upstream product

• 124-41-4 sodium methylate 
• 87444-39-1 5-bromo-3-methylsulfonylpyrazin-2-amine 
• 24241-18-7 2-amino-3,5-dibromopyrazine 
• 4774-10-1 2-amino-3-methoxypyrazine 
• 67-56-1 methanol 

Downstream Products

• 144294-15-5 ethyl 6-bromo-8-methoxy-2-phenylimidazo<1,2-a>pyrazine-3-carboxylate 
• 173253-47-9 5-(N-benzyloxycarbonyl-N-methylamino)-N-(5-bromo-3-methoxy-2-pyrazinyl)-1-naphthalenesulphonamide 
• 67602-06-6 2-amino-3-methoxy-5-phenylpyrazine 
• 489431-66-5 2,5-dibromo-3-methoxypyrazine 
• 476623-17-3 5-bromo-3-methoxy-2-(N-tosyl-6-bromoindol-3-yl)pyrazine 
• 489431-81-4 5-bromo-3-methoxy-2-(N-tosylindol-3-yl)pyrazine 
• 476623-27-5 3-{7-benzyloxy-3-[5-(6-bromo-1H-indol-3-yl)-6-methoxy-pyrazin-2-yl]-1H-indol-4-yl}-1-nitro-butan-2-one 
• 476623-24-2 2-[7-benzyloxy-3-{5-[6-bromo-1-(toluene-4-sulfonyl)-1H-indol-3-yl]-6-methoxy-pyrazin-2-yl}-1-(2-trimethylsilanyl-ethoxymethyl)-1H-indol-4-yl]-propionaldehyde 
• 476623-18-4 2-[7-benzyloxy-3-{5-[6-bromo-1-(toluene-4-sulfonyl)-1H-indol-3-yl]-6-methoxy-pyrazin-2-yl}-1-(2-trimethylsilanyl-ethoxymethyl)-1H-indol-4-yl]-propionic acid 

Relevant articles and documents

Synthesis and cytotoxicity evaluation of novel indolylpyrimidines and indolylpyrazines as potential antitumor agents

Novel indolylpyrimidines and indolylpyrazines have been synthesized as potential antitumor agents. They were screened in a panel of 60 human tumor cell lines in vitro. Compounds 7, 9, 10, 15, 21 exhibited efficiently cytotoxic activities with GI50 values in the low micromolar range against a variety of human cancer cell lines. 2,4-Bis(3′-indolyl)pyrimidine 8 displayed selective cytotoxic activity against IGROV1 tumor cell line with the GI50 value below 0.01 μM.

Design and synthesis of novel methoxypyridine-derived gamma-secretase modulators

The evolution of gamma-secretase modulators (GSMs) through the introduction of novel heterocycles with the goal of aligning activity for reducing the levels of Aβ42 and properties consistent with a drug-like molecule are described. The insertion of a methoxypyridine motif within the tetracyclic scaffold provided compounds with improved activity for arresting Aβ42 production as well as improved properties, including solubility. In vivo pharmacokinetic analysis demonstrated that several compounds within the novel series were capable of crossing the BBB and accessing the therapeutic target. Treatment with methoxypyridine-derived compound 64 reduced Aβ42 levels in the plasma of J20 mice, in addition to reducing Aβ42 levels in the plasma and brain of Tg2576 mice.

Carbonylation as a novel method for the assembly of pyrazine based oligoamide alpha-helix mimetics

The design and synthesis of oligoamide α-helix peptidomimetics is reported. The oligoamide type systems are prepared in a modular fashion by coupling the monomers using palladium-catalyzed carbonylation chemistry. This enabled us to use substrates with a low nucleophilicity, leading to previously unreported pyrazine based oligoamide α-helix mimetics. The proof of principle is given by synthesizing a small set of compounds. Various end-capping groups were introduced and also a mixed multimer was successfully prepared.